ImmuCell (ICCC) Saham Harga
ImmuCell Harga
Pendapatan tumbuh 9,7% per tahun selama 19 tahun terakhir menjadi 27,64 Juta. USD. Laba per saham turun 7,3% per tahun selama 10 tahun terakhir. margin bersih ImmuCell saat ini -3,8%, turun dari -0,4% beberapa tahun lalu.
Harga saham ImmuCell
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham ImmuCell
Pertanyaan yang sering diajukan tentang saham ImmuCell
ImmuCell Corp operates as a biotechnology company, focusing on the development and commercialization of products that improve the health and productivity of dairy and beef cattle. The company's business model revolves around providing innovative animal health solutions, such as First Defense® for newborn calves, which helps strengthen their immune system and prevent diseases. ImmuCell Corp also offers Mast Out®, an FDA-approved treatment for mastitis in lactating dairy cows. Through its dedication to science-driven research and development, ImmuCell Corp aims to enhance animal well-being, increase farmers' efficiency, and ultimately contribute to a sustainable agriculture industry.
ImmuCell Corp is primarily active in the animal health industry.
The main competitors of ImmuCell Corp in the market include companies such as Zoetis Inc., Elanco Animal Health Inc., and Merck & Co. Inc.
ImmuCell Corp is a renowned biotechnology company specializing in the development and production of innovative, preventative animal health products, focusing primarily on the dairy and beef industries. Founded in 1982 and headquartered in Portland, Maine, ImmuCell has established itself as a leader in the field of animal health through its dedication to improving the well-being and productivity of livestock. The company's flagship product, First Defense®, helps protect newborn calves against common diseases while enhancing their natural immune system. ImmuCell Corp remains committed to research and development, continuously striving to provide cutting-edge solutions for animal health challenges.
ImmuCell Corp has achieved significant milestones in its history. One of the notable accomplishments is the development and commercialization of their flagship product, First Defense®. This groundbreaking product has revolutionized the field of animal health by providing a proactive approach to preventing calf scours. Additionally, ImmuCell Corp has successfully expanded its product portfolio to include prominent offerings such as Wipe Out® Dairy Wipes and California Mastitis Test. The company's commitment to research and innovation has garnered recognition, including the prestigious "Best Places to Work in Maine" award. ImmuCell Corp continues to make strides in the animal health industry, solidifying its position as a leader in innovative solutions that enhance herd productivity and profitability.
ImmuCell Corp is primarily present in the United States.
ImmuCell Corp represents a set of core values and a corporate philosophy aimed at advancing animal health and well-being. The company is committed to developing, manufacturing, and selling products that enhance the health and productivity of animals, with a specific focus on the dairy and beef industries. ImmuCell prioritizes quality, innovation, and sustainability, striving to provide effective solutions for preventing and treating various diseases. By leveraging their expertise in animal health, ImmuCell Corp aims to contribute to healthier livestock populations and more efficient farming practices.
7 analis saat ini menilai saham ImmuCell: 6 merekomendasikan beli, 1 tahan, dan 0 jual. Untuk 2026, analis memperkirakan ImmuCell menghasilkan pendapatan 15,14 Juta. USD dan laba per saham -0,24 USD.
Dengan kurs saat ini, saham ImmuCell diperdagangkan pada 8,78 EUR (9,80 USD).
Saham ImmuCell (ICCC) tercatat di 2 bursa, termasuk: NASDAQ (ICCC), Frankfurt (IUL.F).
ImmuCell Corp is a US company specializing in the development and marketing of products for the prevention and treatment of animal diseases, particularly in the dairy industry. The company operates in two main divisions: animal health and veterinary diagnostics. In the animal health division, the flagship product is Calf-Guard®, an immunoglobulin preparation used for preventing diarrhea in calves. In the veterinary diagnostics division, the Bovine IgG Rapid Test Kit is a key product that allows farmers to monitor the health of their animals and detect diseases in a timely manner. ImmuCell Corp aims to expand its product pipeline and enter new markets.
Pendapatan diperkirakan dari ImmuCell adalah 15,14 Juta. USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari ImmuCell adalah -2,17 Juta. USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) ImmuCell saat ini adalah -40,82. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham ImmuCell.
Rasio harga-terhadap-penjualan (PSR) ImmuCell saat ini adalah 5,86. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham ImmuCell.
Skor Kualitas AlleAktien untuk ImmuCell adalah 3/10.
ISIN dari ImmuCell adalah US4525253062. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari ImmuCell adalah 885825. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari ImmuCell adalah ICCC. Simbol ticker digunakan untuk memperdagangkan saham ImmuCell di bursa saham.
Saham ImmuCell
Kelompok Peer ImmuCell
ImmuCell Ticker
ImmuCell FIGI
Semua metrik fundamental dan analisis mendalam ImmuCell
Analisis saham kami untuk saham ImmuCell mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari ImmuCell. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.